A meta-analysis of 29 randomized controlled trials conducted by the National Heart and Lung Institute in London found that serious adverse events between patients receiving statin and placebo were similar. In primary prevention trials, adverse events between those taking statins and placebo were 14.6% and 14.9%, and in the secondary prevention trials adverse events were 9.9% and 11.2% respectively. Researchers say that the side effects data did not come from randomized controlled trials but came from other sources such as observational studies. The only significant adverse event that was more frequent with statins across primary and secondary prevention trials was asymptomatic liver transaminase elevation, which was 0.4% more frequent than placebo.
Image courtesy of [ marin]/FreeDigitalPhotos.net
For more information please visit BMJ